| abstract |
The present invention relates to a composition for suppressing the formation of resistance to a KRAS inhibitor, which is a targeted anticancer drug in the treatment of cancer, and more specifically, to a pharmaceutical composition for suppressing the formation of resistance to a mutant KRAS inhibitor in cancer, comprising a primary cilia formation inhibitor as an active ingredient, to a pharmaceutical composition for preventing or treating cancer, comprising a primary cilia formation inhibitor and a mutant KRAS inhibitor as active ingredients, and to a method of screening for a substance for suppressing the formation of resistance to a mutant KRAS inhibitor in cancer, and the like. The pharmaceutical compositions of the present invention exhibit an effect of suppressing the reoccurrence of KRAS by suppressing primary cilia formation occurring in cancer cells after administration with a mutant KRAS inhibitor, and thus can prevent the formation of resistance to an anticancer-drug that occurs in cancer cells administered with the mutant KRAS inhibitor. |